Efficacy and safety of monoclonal antibodies in neuromyelitis optica spectrum disorders: A survival meta-analysis of randomized controlled trials.

Xu, Xintong; Xie, Lindan; Wei, Lili; Li, Meixuan; Wang, Hao; Zhou, Huanfen; Sun, Mingming; Yang, Mo; Xu, Quangang; Yang, Kehu; Wei, Shihui

Xu, Xintong; Xie, Lindan; Wei, Lili; Li, Meixuan; Wang, Hao; Zhou, Huanfen; Sun, Mingming; Yang, Mo; Xu, Quangang; Yang, Kehu; Wei, Shihui.

Afiliación

Xu X; Medical School of Chinese PLA, Beijing, China.
Xie L; Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China.
Wei L; Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China.
Li M; Evidence-Based Medicine Center, Lanzhou University, Lanzhou, China.
Wang H; Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.
Zhou H; Gansu Medical Guideline Technology Center, Lanzhou University, Lanzhou, China.
Sun M; Evidence-Based Medicine Center, Lanzhou University, Lanzhou, China.
Yang M; Key Laboratory of Evidence Based Medicine and Knowledge Translation of Gansu Province, Lanzhou, China.
Xu Q; Gansu Medical Guideline Technology Center, Lanzhou University, Lanzhou, China.
Yang K; Department of Ophthalmology, Lanzhou University Second Hospital, Lanzhou, China.
Wei S; Department of Ophthalmology, Chinese PLA General Hospital, Beijing, China.

Adv Ophthalmol Pract Res ; 2(3): 100064, 2022.

Article en En | MEDLINE | ID: mdl-37846287

Palabras clave

Adverse events; Free-relapse; Meta-analysis; Monoclonal antibody; NMOSD; Randomized controlled trials

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Systematic_reviews Idioma: En Revista: Adv Ophthalmol Pract Res Año: 2022 Tipo del documento: Article País de afiliación: China

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google